NCT05930080View on ClinicalTrials.gov

Efficacy and Safety of SKCPT in Patients With Knee Osteoarthritis: Phase III Clinical Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

May 19, 2022

Study Completion Date

September 30, 2022

Conditions
Osteoarthritis, Knee
Interventions
DRUG

SKCPT

the randomly assigned subjects took the study drug for 12 weeks

DRUG

Celebrex

the randomly assigned subjects took the study drug for 12 weeks

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

All Listed Sponsors
lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT05930080 - Efficacy and Safety of SKCPT in Patients With Knee Osteoarthritis: Phase III Clinical Trial | Biotech Hunter | Biotech Hunter